Vaxcyte, Inc. (PCVX)
NASDAQ • Healthcare
Last close at November 18, 2026 at 21:00 UTC
Metrics Over Time
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
Vaxcyte’s loss per share topped consensus in the third fiscal quarter of 2026, based on preliminary results reported November 4, 2026, with EPS of -$1.99 topping the -$2.11 estimate by $0.12 even as the company remained in an investment-heavy clinical-stage phase around its vaccine pipeline, including VAX-24. Net income was a loss of roughly $297.1 million, down ~40% year over year from a loss of about $212.8 million, while EPS was -$1.99, down ~28% from -$1.56 a year ago. Operating income came in at a loss of about $308.3 million, reflecting ongoing R&D and operating spend typical for a development-stage biotechnology company without product revenue. Despite the net loss, Vaxcyte generated operating cash flow of about $56.5 million in the quarter. For the next period, consensus calls for EPS of -$2.06 on revenue of $12.5 million.
About Vaxcyte, Inc.
Vaxcyte, Inc. trades on the NASDAQ as PCVX and operates in biotechnology within the healthcare sector. The company is a clinical development-stage vaccine maker that develops protein-based candidates to prevent or manage bacterial infectious diseases, rather than a commercial drug business with product revenue.
Today's Snapshot
The day ended with PCVX 1.5% lower at 58.52, in line with a weaker sector. Vaxcyte said VAX-31, its adult vaccine, met pivotal trial goals.
Trading Volume
Below 10d avg (1.2M)
1.1M
vs S&P 500 Today
Underperforming Market
-1.22%
Updated: November 18, 2026 at 21:15 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$57.42 - $62.88Sell
- RSI (14)41.66Neutral
- Stochastic %K (14, 3, 3)11.07Buy
- MACD Level (12, 26)-0.32Sell
Peers & Related Assets
Get premium market insights delivered directly to your inbox.